Cellis has been featured in Nature’s Biopharma Dealmakers, showcasing our innovative macrophage–drug conjugate (MDC) platform and its potential to transform solid-tumor cell therapy.
The article highlights the unique advantages of our MDC technology, its dual mechanism of action, and its potential to overcome key challenges in solid-tumor treatment. It also outlines our progress toward the clinic, with first-in-human trials of MDC-735 planned for 2025 in collaboration with Stanford University and University Hospital Zurich.
If you’re interested in the future of oncology and how Cellis is tackling solid tumors with an “off-the-shelf” cell therapy, this is a must-read.
📖 Read the full article: https://www.nature.com/articles/d43747-025-00009-1
